136 related articles for article (PubMed ID: 38730207)
1. Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma.
Yoon SE; Cho H; Berning P; Cho J; Kim HY; Yoon DH; Schmit N; Kim SJ; Kim WS
Ann Hematol; 2024 May; ():. PubMed ID: 38730207
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma.
Chen X; Zhao S; Wang H; Fu C; Tian R; Zou L
Quant Imaging Med Surg; 2021 Apr; 11(4):1220-1233. PubMed ID: 33816162
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
5. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Kwong YL; Chan TSY; Tan D; Kim SJ; Poon LM; Mow B; Khong PL; Loong F; Au-Yeung R; Iqbal J; Phipps C; Tse E
Blood; 2017 Apr; 129(17):2437-2442. PubMed ID: 28188133
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL.
Lim SH; Hyun SH; Kim HS; Lee JY; Yoo KH; Jung KS; Song HN; Cho J; Park S; Ko YH; Kim SJ; Choi JY; Kim WS
Bone Marrow Transplant; 2016 Jun; 51(6):807-12. PubMed ID: 26855154
[TBL] [Abstract][Full Text] [Related]
8. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
9. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
Kim WS; Oki Y; Kim SJ; Yoon SE; Ardeshna KM; Lin Y; Ruan J; Porcu P; Brammer JE; Jacobsen ED; Yoon DH; Suh C; Suarez F; Radford J; Budde LE; Kim JS; Bachy E; Lee HJ; Bollard CM; Jaccard A; Kang HJ; Inman S; Murray M; Combs KE; Lee DY; Advani R; Gunter KC; Rooney CM; Heslop HE
Ann Hematol; 2021 Oct; 100(10):2529-2539. PubMed ID: 34304287
[TBL] [Abstract][Full Text] [Related]
10. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of bone marrow (18)F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma].
Zhang Y; Zhou J; Wang L; Li JY; Ding CY
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):885-890. PubMed ID: 33113633
[No Abstract] [Full Text] [Related]
12. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
14. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
[No Abstract] [Full Text] [Related]
15. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
16. Appropriate timing to perform an interim
Wang R; Zhang Y; Fan Q; Jiang M; Zou L; Su M
Ann Hematol; 2024 Mar; 103(3):885-892. PubMed ID: 38030892
[TBL] [Abstract][Full Text] [Related]
17. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab in combination with intrathecal chemotherapy and radiation for treatment of isolated cerebral nervous system relapse in a patient with extranodal NK/T cell lymphoma: a case report.
Lipsitt AE; Hung JY; Langevin AM
J Med Case Rep; 2021 Mar; 15(1):102. PubMed ID: 33663601
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic Value of Interim
Wang TS; Qiao WL; Xing Y; Zhao JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):731-734. PubMed ID: 34105465
[TBL] [Abstract][Full Text] [Related]
20. Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.
Kim SJ; Ryu KJ; Park B; Yoon SE; Cho J; Park Y; Kim WS
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
